Chapter 1. Research Objective
1.1 Objective, Definition & Scope
1.2 Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Forecast - Estimation & Approach
1.2.4 Assumptions & Assessments
1.3 Insights and Growth - Relevancy Mapping
1.3.1 FABRIC Platform
1.4 Data mining & efficiency
Chapter 2. Executive Summary
2.1 Cell & Gene Therapy Market Overview
2.2 Interconnectivity & Related markets
2.3 Ecosystem Map
2.4 Cell & Gene Therapy Market Business Segmentation
2.5 Cell & Gene Therapy Market Geographic Segmentation
2.6 Competition Outlook
2.7 Key Statistics
Chapter 3. Strategic Analysis
3.1 Cell & Gene Therapy Market Revenue Opportunities
3.2 Cost Optimization
3.3 Covid19 aftermath - Analyst view
3.4 Cell & Gene Therapy Market Digital Transformation
Chapter 4. Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PEST Analysis
4.2.1 Political
4.2.2 Economic
4.2.3 Social
4.2.4 Technological
4.3 Market Impacting Trends
4.3.1 Positive Impact Trends
4.3.2 Adverse Impact Trends
4.4 Porter's 5-force Analysis
4.5 Market News - By Segments
4.5.1 Organic News
4.5.2 Inorganic News
Chapter 5. Market Segmentation
The Cell & Gene Therapy Market has been analysed to include the below segmentation:
BY THERAPY
• GENE THERAPY
• CELL THERAPY
BY APLICATIONS
• DERMATOLOGY
• MUSCULOSKELETAL
• ONCOLOGY
• GENETIC DISORDERS
• OTHERS
BY END-USERS
• HOSPITALS
• WOUND CARE CENTERS
• CANCER CARE CENTERS
• ASCs
• OTHERS
Chapter 5A. Regional Segmentation
The Cell & Gene Therapy Market has been analysed by studying the following regions:
North America
• BY THERAPY
• BY APLICATIONS
• BY END-USERS
Europe
• BY THERAPY
• BY APLICATIONS
• BY END-USERS
APAC
• BY THERAPY
• BY APLICATIONS
• BY END-USERS
LatAm
• BY THERAPY
• BY APLICATIONS
• BY END-USERS
MEA
• BY THERAPY
• BY APLICATIONS
• BY END-USERS
**The Regions are further studied to analyse the major countries within the respective regions. The coverage of the country level data is dynamic and is updated regularly based on the market movements. Normally, the countries covered in the report include:
• North America - United States, Canada, Mexico;
• Europe - United Kingdom, France, Italy, Germany, Spain, Rest of Europe;
• Asia Pacific - China, India, Japan, South Korea, Rest of APAC;
• Middle East & Africa - South Africa, GCC Countries, Rest of MEA;
• Latin America - Brazil, Argentina, Rest of LatAm;
Chapter 6. Market Use case studies
Chapter 7. KOL Recommendations
Chapter 8. Investment Landscape
8.1 Cell & Gene Therapy Market Investment Analysis
8.2 Market M&A
8.3 Market Fund Raise & Other activity
Chapter 9. Cell & Gene Therapy Market - Competitive Intelligence
9.1 Company Positioning Analysis
9.1.1 Positioning - By Revenue
9.1.2 Positioning - By Business Score
9.1.3 Legacy Positioning
9.2 Competitive Strategy Analysis
9.2.1 Organic Strategies
9.2.2 Inorganic Strategies
Chapter 10. Key Company Profiles
*The Cell & Gene Therapy Market Report profiles companies based on the material impact they have on the market ecosystem. These are hence, to be read as 'Key Players' and not necessarily 'Market Leaders'.
Companies are typically profiled to include:
10.x.1 Company Fundamentals
10.x.2 Performance Overview
10.x.3 Product Overview
10.x.4 Recent Developments
Key Companies profiled in this report include:
• GILEAD SCIENCES
• SPARK THERAPEUTICS
• NOVARTIS
• AMGEN
• OSIRIS THERAPEUTICS
• DENDERON
• ORGANOGENESIS
• VERICEL
• ANTEROGEN
• TEGO SCIENCES
• JAPAN TISSUE ENGINEERING (J-TEC)
• JCR PHARMACEUTICALS
• MEDIPOST
• MOLMED
• AVITA MEDICAL
• COLLPLANT
• BIOSOLUTION
• STEMPEUTICS RESEARCH
• KOLON TISSUE GENE
• ORCHARD THERAPEUTICS
• SIBIONO GENETECH
• NUVASIVE
• CORESTEM
• PHARMICELL
• SHANGHAI SUNWAY BIOTECH
• RMS REGENERATIVE MEDICAL SYSTEM
• TAKEDA PHARMACEUTICAL COMPANY
Chapter 11. Appendix
11.1 About AllTheResearch (ATR)
11.2 ATR Services
11.3 Author details
11.4 Terms & Conditions
11.5 Contact us
Log in / Register
